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Allergy diagnosis and treatment depend on cross-reactivity 
between extracts from similar species, and allergenic proper-
ties may vary according to the environmental circumstances 
where an extract is produced. For the development of reliable 
allergy diagnostics and immunotherapeutics, standardization 
of allergen extract is a prerequisite.1 However, in Korea, all 
commercial allergen extracts in clinical use are imported from 
the United States of America or European countries. In addi-
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Precise allergy diagnosis and effective allergen specific immunotherapy are largely dependent on the quality of allergen extract. A 
new extract of Dermatophagoides farinae was commercially developed by Prolagen. The allergenic properties of the new extract 
were compared with those of other commercial products. The allergenic properties of the new extract were compared according 
to protein concentration, protein profiles, major allergen (Der f 1) contents, and allergenic potency to those for three commer-
cially available extracts imported in Korea (Jubilant HollisterStier Allergy, Lofarma S.p.A., and Stallergenes Greer). Protein con-
centrations varied up to 2.62-fold (0.404 to 1.057 mg/mL), and Der f 1 contents varied up to 11.3-fold (3.597 to 40.688 μg/mL). 
Protein profiles of the extracts showed no major discrepancies, although there were some differences in SDS-PAGE band intensi-
ties, reflecting protein concentrations. Allergen potency ranged from 37038 to 60491 PAU/mL. The Prolagen product was highest 
in terms of protein concentration and allergen potency. The Lofarma product displayed Der f 1 content similar to that in Prolagen 
(19.4 μg/mg vs. 19.3 μg/mg). Endotoxin levels varied 8.9-fold (1020 to 8985 EU/mL). The newly developed house dust mite extract 
showed equal or better allergenic properties than available commercial extracts. This new product may be useful for better diag-
nostics and allergen-specific immunotherapeutics.
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tion, some commercial products are no longer available due 
to strengthened regulations.2,3 Thus, in Korea, efforts have been 
made to standardize locally produced allergens since 2009 with 
support from the Korea Center for Disease Control and Pre-
vention.4 Previous studies have been performed for standard-
ization of extracts for house dust mite (HDM),5 cockroach,6 
pollens of regional importance,7 insect venom component al-
lergen (Pac c 3 from Pachycondyla chinensis),8 and buckwheat.9 
The stabilities of extracts for HDM,10 cockroach,11 and pollens12 
have also been studied. Standardization of food allergens, in-
cluding cereals and various regionally important fish species, 
is ongoing.
A company, ‘Prolagen (Seoul, Korea)’, established in 2017, 
obtained good manufacturing practice accreditation for the 
production of allergen extracts for allergy immunotherapeu-
tics from the Ministry of Food and Drug Safety in 2019. Previ-
ously, eight skin prick test reagents produced from Prolagen 
were shown to be comparable to those of imported products.13
In this study, we compared the allergen extract for D. fari-
nae produced by Prolagen with imported ones. Protein con-
centrations, major allergen contents, endotoxin levels, and po-
tency among these commercially available products were 
compared by in vitro methods.
The Prolagen HDM allergen extract was prepared as de-
scribed previously.5 For comparison, HDM extracts were ob-
tained from Jubilant HollisterStier Allergy (Spokane, WA, 
USA), Lofarma S.p.A. (Milano, Italy), and Stallergenes Greer 
(Boston, MA, USA). All extracts investigated in this study are 
manufactured as immunotherapeutic reagents, except the Lo-
farma product, which is for skin testing. Also, Stallergenes 
Greer’s product is for veterinary use, not human use.
Protein concentrations were determined using a Bradford 
assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Con-
centrations of major allergens Der f 1 and Der f 2 were quanti-
fied using two-site ELISA kits from Indoor Biotechnologies 
Inc. (Charlottesville, VA, USA). Protein concentrations were de-
termined to be 404–1057 μg/mL. Among the D. farinae prod-
ucts, the Prolagen product had the highest concentrations of 
Der f 1 and Der f 2, while the Stallergenes Greer product li-
censed for veterinary use had the lowest concentrations (Ta-
ble 1). Der f 1 and Der f 2 content varied about 5.6- to 14.0-fold, 
respectively. The sum of these two major allergen contents dif-
fered by up to 6.9-fold, and the sum of these major allergen 
concentrations differed up to approximately 3.4-fold even af-
ter conversion into μg/mg protein concentrations. The ratio of 
Der f 1 to Der f 2 varied from 1:0.404 to 1:1.396 (3.5-fold) (Ta-
ble 1). Der f 1/2 ratio may be affected by diet14 and tempera-
ture.15 Extraction method may also affect Der f 1/2 ratio.5 
Protein profiles of the commercial extracts were compared 
by 15% SDS-PAGE (20 μL/well). Der f 1 and Der f 2 were de-
tected with anti-recombinant Der f 1 monoclonal antibody 
(mAb) 3D716 and anti-recombinant Der f 2 mAb 2F3817 as de-
scribed previously.5 IgE reactive components were probed with 
pooled serum samples (1:4 diluted). Serum samples were kind-
ly provided by TRINA BIOREACTIVES (Naenikon, Switzerland). 
More intense bands of high molecular weight proteins were seen 
with the Hollister-Stier products, whereas additional strong 
bands were noted in the Prolagen product (Fig. 1A). The stron-
gest IgE reactivity to a 14 kDa allergen, putative Der f 2, was 
shown by IgE immunoblot analysis in all examined extracts 
(Fig. 1B). Interestingly, relatively poor recognition of Der f 2 
was observed for the Stallergenes Greer extract, even though 
similar recognition was shown with mAb 2F38. This is possibly 
due to polymorphism of Der f 2: mAb may recognize highly 
conserved regions, whereas human IgE antibodies recognize 
polymorphic residues. Weak IgE reaction to a 25 kDa compo-
nent, putative Der f 1, was also displayed. MAbs strongly recog-
nized Der f 1 (Fig. 1C) and Der f 2 (Fig. 1D) in the extracts. De-
graded Der f 1 was detected in the Lofarma product (Fig. 1C). 
A previous study used intradermal skin tests to determine 
the potency of HDM extracts5 because this method is known 
to be more sensitive than skin prick tests.18 However, we pro-
duced a new in-house reference preparation and carried out 
skin prick tests to meet the European standard.19,20 A newly es-
tablished potency was designated as Prolagen Allergy Unit 
(PAU). Competitive inhibition ELISA was performed, and al-
lergenic potency was determined using 50% inhibitory concen-
trations of each allergen extract.21 Allergen potencies differed 
up to about 1.6-fold, 37038–60491 PAU/mL (Fig. 2 and Table 2), 
which is similar to the sum of major allergen contents. 
Endotoxin levels in extracts were measured using a kinetic 
Limulus amoebocyte lysate assay (Kinetic-QCL, Bio Whittak-
er, LONZA, Basel, Switzerland). Endotoxin levels in the ex-
tracts ranged from 1020–9110 EU/mL (up to 8.9-fold). Endo-
Table 1. Contents of D. farinae Allergen Extracts Commercially Available in Korea
Product Protein concentration
Major allergen content
Der f 1  Der f 2  Sum (Der f 1 & 2)
  Manufacture Lot No. Licensed use μg/mL μg/mL μg/mg μg/mL μg/mg μg/mL μg/mg
H, HollisterStier E1900466 Human 523 3.6 6.9 3.5 6.8 7.1 13.6
L, Lofarma 190702 Human 569 11.0 19.4 6.7 11.8 17.7 31.2
G, Greer 363113 Veterinary 404 5.0 12.4 2.0 5.0 7.1 17.5
P, Prolagen DF18001 Human 1057 20.3 19.3 28.4 26.9 48.8 46.1
Average 638.3 10.0 14.5 10.2 12.6 20.2 27.1
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toxin levels per mg of protein differed by up to 6.9-fold (2524.8 
to 17418.7) (Table 3). Endotoxin levels in commercial HDM 
extract vary up to 1000-fold (31 to 5200 EU).22 The facultative 
intracellular bacteria Bartonella may be a mite symbiont and 
is thought to be the major source of endotoxin in HDM ex-
tracts.23 Although difficult, endotoxin levels should be lowered 
to minimize possible side effects.
Varying composition and allergen content in commercial 
HDM allergen extracts commonly used for allergy diagnosis 














































Fig. 1. Protein and allergen profiles of commercial Dermatophagoides farinae extracts.  (A) Proteins (20 μL each) were separated onto 15% SDS-PAGE. 
(B) IgE reactive components were then probed with pooled patient sera. Der f 1 (C) and Der f 2 (D) allergens were detected with the use of monoclonal 
antibodies.
Fig. 2. Allergen potencies of commercial Dermatophagoides farinae ex-
tracts. Prolagen product with defined allergen units was coated, and 































Table 2. Comparison of Allergen Potencies of Commercial D. farinae Ex-
tracts
Product Potency (Allergy unit)





H, HollisterStier 10000 AU/mL 916.8 37038 (46125)
L, Lofarma 100 DBU/mL 561.3 60491 (75332)
G, Greer 11000 PNU/mL 703.9 48244 (60081)
P, Prolagen* 150000 PAU/mL 580.9 58453 (72794)
Average 690.8 51057 (63583)
*Available as freeze-dried powder.
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and immunotherapy have been described.24,25 Analysis of com-
mercial allergen extracts of HDM may provide useful informa-
tion for clinicians to select optimal products. Induction of 
blocking antibodies may vary according to the allergen prod-
ucts.26 The IgE reactivity of allergens may be affected by not 
only species, but also by polymorphism of individual allergens, 
especially for Der f 2 and Der p 2.27,28 Different sensitization 
patterns with different disease entities, respiratory or cutane-
ous allergies, also imply that careful product selection may in-
fluence the efficacy of immunotherapy.29 For patients with re-
spiratory allergy sensitized to HDM, better efficacy is expected 
with products containing extracts from raw materials with 
abundant mite feces, which contain more group 1 and 2 aller-
gens. However, patients with cutaneous allergy are more likely 
to benefit from products with whole body extracts that may 
contain more minor allergens.
We analyzed the various commercial products licensed for 
immunotherapeutic, skin test, and veterinary use. In fact, 
these products were the only products we could obtain at the 
moment in Korea, although we hope to compare more prod-
ucts. It should be mentioned that the major allergen concen-
trations and potency of the reagents should differ in relation 
to the purpose of clinical application.
In conclusion, the D. farinae extract newly manufactured 
by Prolagen is comparable to imported products. This product 
may be useful for the development of better diagnostics and 
allergen-specific immunotherapeutics. 
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